IKNA: Ikena Oncology, Inc. Price/Earnings to Growth Multiple

Symbol and logo of brand Ikena (IKNA)

Ikena Oncology, Inc. (IKNA) is implementing precision therapy to block genetic tumor growth pathways. The company is developing targeted molecules against RAS and Hippo mutations, although high R&D costs are depleting reserves. The ratio of cost to business expansion rates on the GURU.Markets terminal chart reflects market dynamics, where the 0.00 level captures the current state of the asset's fundamental valuation.

Price/Earnings to Growth Ratio: Ikena Oncology Inc. (IKNA) for 07/04/2022 - 08/09/2025

Analytical breakdowns for Ikena (IKNA)

- share price and consensus valuation forecast:
Fundamental company analysis:IKNA Ikena
Mass-produced product of Ikena Oncology Inc.

Ikena Oncology, Inc. (IKNA) development of innovative oncology drugs with long-term patent protection defines the business's long-term outlook, which is clearly reflected in the PEG ratio dynamics. This coefficient compares the P/E market multiple with earnings growth rates, allowing investors to identify asset undervaluation: a value below one signals high fundamental stability and an absence of overpayment for the company's future growth.

Competing companies

Price/Earnings to Growth Multiple BeiGene Ltd ONC|PEG Multiple HALO (halozyme.com)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen (URGN) - Price/Earnings to Growth Ratio|Bicara Bio - Growth-Adjusted Payback Ratio|PSNL (Personalis Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca, Inc. ERAS|PEG Multiple DCTH|YMAB - Price to Earnings Adjusted for Growth Rate|Aura Biosciences Inc - Price/Earnings to Growth Multiple|PEG Multiple Candel Therapeutics CADL|accuray.com - PEG Multiple|SLS: Price/Earnings to Growth Ratio|ACTU (actuatetherapeutics.com) - Price/Earnings to Growth Multiple|CTOR - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio tuhurabio.com|PEG Multiple Protara Tx|Price/Earnings to Growth Multiple FATE (Fate Therapeutics Corp)|Price/Earnings to Growth Ratio WHWK (Aadi Bioscience)|TScan Therapeutics, Inc. - Price/Earnings to Growth Multiple|Champions Oncology (CSBR) - Price to Earnings Adjusted for Growth Rate|XBiotech - PEG Multiple|CEL-SCI (CVM) - Price/Earnings to Growth Multiple|OS Therapies Inc (OSTX) - Price/Earnings to Growth Ratio|radiopharmtheranostics.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Artiva Biotherapeutics Inc.|Price to Earnings Adjusted for Growth Rate Adlai Nortye Ltd. ANL|PEG Multiple VERU|TPST - Price to Earnings Adjusted for Growth Rate|PEG Multiple XLO (Xilio Therapeutics)|RENB - Price/Earnings to Growth Multiple|muraloncology.com - PEG Multiple|KAPA - PEG Multiple|OKUR: PEG Multiple|Market Cap to Earnings and Growth Ratio GDTC (CytoMed Therapeutics Ltd)|CRIS (curis.com) - PEG Multiple|Apollomics, Inc. (APLM) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple THAR (Tharimmune, Inc.)|ADVB (Advanced Biomed) - Growth-Adjusted Payback Ratio|PEG Multiple GNPX (Genprex Inc)|calidibio.com (CLDI) - Price to Earnings Adjusted for Growth Rate|sunshinebiopharma.com - PEG Multiple|Price to Earnings Adjusted for Growth Rate Xenetic Biosciences, Inc.|SLRX (Salarius Pharmaceuticals) - Price/Earnings to Growth Multiple|Price/Earnings to Growth Multiple Purple Biotech Ltd.|AONC (American Oncology Network Inc) - PEG Multiple|Price/Earnings to Growth Multiple BeOne Medicines (BGNE)|PEG Multiple CKPT|ELEV - Price to Earnings Adjusted for Growth Rate|iCAD Inc. - Price/Earnings to Growth Multiple|NTBL - Price/Earnings to Growth Multiple|VIRX - Price/Earnings to Growth Ratio|MOR - PEG Multiple|NAYA: PEG Multiple|Ascentage Pharma Group (AAPGV) - PEG Multiple